Bulletins - Administration
Filter by category:
AdministrationAdverse drug reactionsCannabis-based productsComplementary and Alternative Medicines (CAMs)COVID-19Drug comparisonsInteractionsNew medicineOtherPharmacokineticPregnancy/BreastfeedingCan transdermal patches be halved? - May 16, 2023
Sometimes it is necessary to give a lower patch dose than is available. This problem has become more frequent with supply issues for some patch doses. Manipulation of a dose form can affect pharmacokinetics and stability, although there are very few studies involving patches. Cutting or occluding...
Empagliflozin and dulaglutide in type 2 diabetes - April 6, 2021
NZ is funding two medicines in new classes for the treatment of type 2 diabetes.1 These will be second line options after metformin, and favoured for patients at high risk of cardiovascular or renal complications. They are subject to special authority criteria.1-3 Empagliflozin, a sodium-glucose ...
Oral Anticoagulants – Rivaroxaban and Dabigatran - October 1, 2019
Rivaroxaban (Factor Xa inhibitor), dabigatran etexilate (direct thrombin inhibitor), or warfarin (vitamin K epoxide reductase inhibitor) can be used as oral anticoagulants for most indications. Warfarin remains first line for patients with mechanical heart valves or severe chronic kidney disease....
Repackaging dabigatran into compliance packs - October 8, 2018
Compliance packs
With an ageing population there is increasing incidence of multimorbidity and polypharmacy. This leads to complex dosing regimens.
Compliance aids, such as the Medico Paks® or unit dose medication sachets, are widely used to manage complex medication regimes, and help remind...